RxDoctor Payments Data

Susan Swanson, MD

Ophthalmology · Dallas, TXNPI 1942372339

Payments from drug & device makers

$1,939in general payments, 2019–2025

Across 72 payments — averaging $26.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$622
  • Alcon$218
  • AbbVie$151
  • Harrow Eye, LLC$149
  • Bausch & Lomb Americas Inc.$133
  • Coopervision Inc.$100
  • plus $565 from 14 others

What the payments were for

  • Consulting fees$55629%
  • Speaking & faculty fees$231%
  • Food & beverage$1,36070%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,939 in reported general payments places this provider in the 45th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$383,375
Medicare patients
1,323
Services billed
4,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine241$184,079
MieboPerfluorohexyloctane/Pf116$86,653
XiidraLifitegrast86$80,278
Cyclosporine136$48,470
LumiganBimatoprost70$31,082
Travoprost64$11,577
Prednisolone Acetate289$10,061
VevyeCyclosporine13$9,715
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol43$7,425
Latanoprost541$5,410
SimbrinzaBrinzolamide/Brimonidine Tart21$5,289
VyzultaLatanoprostene Bunod12$4,145
RocklatanNetarsudil Mesylat/Latanoprost12$3,970
Timolol Maleate187$3,438
Fluorometholone25$1,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$151$215,161311 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$133$171,077214 claims
Harrow Eye, LLCVevye$149$9,71513 claims
AlconSimbrinza$218$5,28921 claims
Aerie Pharmaceuticals, Inc.Rocklatan$20$3,97012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →